- Reuters•2 hours ago
Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.
- The Wall Street Journal•9 hours ago
AT&T and Verizon Communications pulled much of their advertising from Google over concerns that their ads may have run alongside controversial videos, extending the financial impact of a controversy.
- Reuters•14 hours ago
Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease. By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines. The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York.
GSK : Summary for GlaxoSmithKline PLC - Yahoo Finance
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||42.19 - 42.35|
|52 Week Range||37.20 - 45.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||93.26|
|Dividend & Yield||2.00 (4.74%)|
|1y Target Est||N/A|